{"filing":{"accession_number":"0001193125-26-262950","cik":"0001861560","ticker":"NUVL","company_name":"Nuvalent, Inc.","form":"8-K","filing_date":"2026-06-09","report_date":null,"primary_document":"d137459d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1861560/000119312526262950/d137459d8k.htm"},"events":[{"id":4282,"run_id":3736,"accession_number":"0001193125-26-262950","anchor_item_number":"1.01","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.97,"summary":"Nuvalent entered into an Agreement and Plan of Merger with GlaxoSmithKline LLC on June 9, 2026, whereby GSK will commence a tender offer at $124.00 per share, followed by a merger if conditions are satisfied. This is a material acquisition and change of control transaction.","company_name":"Nuvalent, Inc.","ticker":"NUVL","filing_date":"2026-06-09","items":[{"id":5397,"accession_number":"0001193125-26-262950","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.99,"reasoning":"Nuvalent entered into an Agreement and Plan of Merger with GlaxoSmithKline LLC on June 9, 2026, whereby Purchaser will commence a tender offer at $124.00 per share, followed by a merger if conditions are satisfied. This is a material acquisition/change of control transaction involving entry into a definitive merger agreement with a specified purchase price and transaction structure, clearly falling under Item 1.01 (Entry into a Material Definitive Agreement) and the ma_activity event type.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-09T11:04:10.930417+00:00","company_name":"","ticker":null,"filing_date":""},{"id":5398,"accession_number":"0001193125-26-262950","item_number":"7.01","item_title":"Other Events.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"The filing discloses execution of a Merger Agreement by Ultimate Parent with respect to Nuvalent, announced via press release on June 9, 2026. The disclosure references a tender offer and merger transaction, with detailed discussion of closing conditions, regulatory approvals, and transaction timing. This constitutes entry into a material acquisition/change of control transaction, which is a core M\u0026A activity event requiring 8-K disclosure.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-09T11:04:10.930417+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":5397,"accession_number":"0001193125-26-262950","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.99,"reasoning":"Nuvalent entered into an Agreement and Plan of Merger with GlaxoSmithKline LLC on June 9, 2026, whereby Purchaser will commence a tender offer at $124.00 per share, followed by a merger if conditions are satisfied. This is a material acquisition/change of control transaction involving entry into a definitive merger agreement with a specified purchase price and transaction structure, clearly falling under Item 1.01 (Entry into a Material Definitive Agreement) and the ma_activity event type.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-09T11:04:10.930417+00:00","company_name":"Nuvalent, Inc.","ticker":"NUVL","filing_date":"2026-06-09"},{"id":5398,"accession_number":"0001193125-26-262950","item_number":"7.01","item_title":"Other Events.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"The filing discloses execution of a Merger Agreement by Ultimate Parent with respect to Nuvalent, announced via press release on June 9, 2026. The disclosure references a tender offer and merger transaction, with detailed discussion of closing conditions, regulatory approvals, and transaction timing. This constitutes entry into a material acquisition/change of control transaction, which is a core M\u0026A activity event requiring 8-K disclosure.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-09T11:04:10.930417+00:00","company_name":"Nuvalent, Inc.","ticker":"NUVL","filing_date":"2026-06-09"}]}